Código QR

Brinzolamide-timolol suspension: acceptability and side effect profile

MD Doherty, SG Fraser, PS PhelanSunderland Eye Infirmary, Sunderland, Tyne and Wear, UKBackground: This study aimed to determine the frequency, nature, and impact of side effects associated with the use of brinzolamide-timolol suspension, a topical ocular antihypertensive preparation.Methods: A ques...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Doherty MD, Fraser SG, Phelan PS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/35c44b76edd847e5b088353985bb05c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa K, et al.
Publicado: (2014)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
por: Yoshikawa K, et al.
Publicado: (2014)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau A, et al.
Publicado: (2013)

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
por: Altafini R, et al.
Publicado: (2015)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
por: Syed MF, et al.
Publicado: (2011)

Patient perspectives when switching from Cosopt&reg; (dorzolamide-timolol) to Azarga&trade; (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger GA, et al.
Publicado: (2012)

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
por: Makoto Ishikawa, et al.
Publicado: (2009)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue K, et al.
Publicado: (2015)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz K, et al.
Publicado: (2011)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nagayama M, et al.
Publicado: (2014)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo JS, et al.
Publicado: (2016)

Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Henny JM Beckers, et al.
Publicado: (2009)

A patient preference comparison of Azarga&trade; (brinzolamide/timolol fixed combination) vs Cosopt&reg; (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Thomas K Mundorf, et al.
Publicado: (2008)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
por: Michele Iester
Publicado: (2008)

Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nakajima M, et al.
Publicado: (2013)

Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study
por: Shusaku Ishikawa, et al.
Publicado: (2008)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension
por: Whitson JT, et al.
Publicado: (2013)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Effect of dorzolamide/timolol combination on the visual field in glaucoma
por: Takeda S, et al.
Publicado: (2014)

Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
por: Fechtner RD, et al.
Publicado: (2011)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão MLS, et al.
Publicado: (2014)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Yoshimi Nakamura, et al.
Publicado: (2009)

Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension
por: Sharma S, et al.
Publicado: (2015)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
por: Radcliffe NM
Publicado: (2014)

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure
por: Takeda S, et al.
Publicado: (2014)

Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients
por: Adam M Moss, et al.
Publicado: (2010)

Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
por: Jaime Pablo Kelly Rigollet, et al.
Publicado: (2011)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa VP, et al.
Publicado: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Douglas J Rhee, et al.
Publicado: (2008)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner SF, et al.
Publicado: (2019)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
por: Anders Bergstr&ouml;m, et al.
Publicado: (2009)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas W, et al.
Publicado: (2011)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

Rational use of the fixed combination of dorzolamide &ndash; timolol in the management of raised intraocular pressure and glaucoma
por: Jason Yeh, et al.
Publicado: (2008)